Insight of immune checkpoint inhibitor related myocarditis.

Autor: Pi JK; Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China., Chen XT; Animal Experimental Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China., Zhang YJ; Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China., Chen XM; Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China., Wang YC; Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China., Xu JY; Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China., Zhou JH; Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China., Yu SS; Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China., Wu SS; Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China. Electronic address: wusisi@wchscu.cn.
Jazyk: angličtina
Zdroj: International immunopharmacology [Int Immunopharmacol] 2024 Dec 25; Vol. 143 (Pt 3), pp. 113559. Date of Electronic Publication: 2024 Nov 12.
DOI: 10.1016/j.intimp.2024.113559
Abstrakt: As the understanding of immune-related mechanisms in the development and progression of cancer advances, immunotherapies, notably Immune Checkpoint Inhibitors (ICIs), have become integral in comprehensive cancer treatment strategies. ICIs reactivate T-cell cytotoxicity against tumors by blocking immune suppressive signals on T cells, such as Programmed Death-1 (PD-1) and Cytotoxic T-lymphocyte Antigen-4 (CTLA-4). Despite their beneficial effects, ICIs are associated with immune-related adverse events (irAEs), manifesting as autoimmune side effects across various organ systems. A particularly alarming irAE is life-threatening myocarditis. This rare but severe side effect of ICIs leads to significant long-term cardiac complications, including arrhythmias and heart failure, and has been observed to have a mortality rate of up to 50% in affected patients. This greatly limits the clinical application of ICI-based immunotherapy. In this review, we provide a comprehensive summary of the current knowledge regarding the diagnosis and management of ICI-related myocarditis. We also discuss the utility of preclinical mouse models in understanding and addressing this critical challenge.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: